FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to a method for reducing or preventing acerbation or progression of symptoms of benign prostatic hyperplasia (BPH).
EFFECT: proposed method, which involves administering a therapeutically effective amount of peptide containing an amino acid sequence with SEQ ID NO: 66, reduces acerbation or progression of symptoms of BPH in accordance with the International Prostatic Symptom Scale (IPSS) by more than 10%.
16 cl, 8 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREVENTING ONSET OR REDUCING INCIDENCE OF ACUTE URINARY RETENTION | 2017 |
|
RU2721538C1 |
| COMPOSITIONS AND METHODS FOR IMPROVING SEXUAL FUNCTION | 2018 |
|
RU2739916C1 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
| ANTIBODIES DIRECTED AGAINST Fc-RECEPTOR-LIKE PROTEIN 5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2774158C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND TREATMENT | 2020 |
|
RU2806915C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
